8-K: FONAR to Go Private in $90M Deal Led by CEO

FONAR Corporation has entered into a definitive merger agreement to be acquired by an acquisition group led by its CEO for $90 million in cash, taking the company private.

Summary

• FONAR Corporation has signed a definitive merger agreement to be acquired by FONAR, LLC, an entity formed by a group led by CEO Timothy Damadian, for approximately $90 million.
• The transaction will take FONAR private, with its common stock delisting from Nasdaq.
• Shareholders will receive cash consideration: $19.00 per share for Common Stock and Class B Common Stock, $6.34 per share for Class C Common Stock, and $10.50 per share for Class A Non-voting Preferred Stock.
• The offer price for common stock represents a 31.5% premium to the closing price on the last trading day before the announcement, a 21.9% premium to the price before the initial proposal, and a 39.7% premium over the 90-day average closing price ending June 30, 2025.
• The transaction is subject to stockholder approval, including a majority vote from disinterested stockholders, and customary regulatory approvals.
• The deal is not contingent on financing, with $35 million in debt committed by OceanFirst Bank, N.A., $10 million in additional debt, and $45 million in equity from the Acquisition Group and other investors.
• Certain stockholders, members of the Acquisition Group, have entered into voting agreements to support the merger, representing 6,622,872 voting securities, which will not be counted for disinterested stockholder approval.

Sentiment

Score: 8

Explanation: The sentiment is highly positive for shareholders due to the substantial premium offered in an all-cash take-private transaction, unanimously recommended by the independent Special Committee and the Board. The secured financing further de-risks the deal for shareholders. While the company will delist, the immediate cash value is a strong positive.

Positives

• A significant premium is offered to shareholders: 31.5% over the last trading day's closing price, 21.9% over the price before the initial proposal, and 39.7% over the 90-day average.
• The transaction is an all-cash deal, providing liquidity and certainty of value to public shareholders.
• The Special Committee, composed of independent directors, unanimously recommended the merger, determining it to be fair and in the best interests of the company and its stockholders.
• The Board, excluding interested directors, also unanimously approved the merger.
• Financing for the transaction is secured and not contingent on the Company's ability to obtain it, reducing execution risk.

Negatives

• The company will be delisted from Nasdaq, removing public trading opportunities for investors.
• Public shareholders will no longer participate in any future growth or upside of the company.
• The 'take-private' nature of the deal, led by existing management, could raise questions about potential conflicts of interest, although a Special Committee and disinterested stockholder vote are in place to mitigate this.
• A termination fee of $450,000 (less Parent's expenses) is payable by the Company under certain circumstances, which could be a deterrent to superior offers.

Risks

• Failure to obtain the 'Requisite Company Vote' from stockholders, including the Disinterested Stockholder Approval.
• Failure to satisfy other closing conditions, such as regulatory approvals (e.g., antitrust laws, governmental consents).
• The occurrence of any event, change, or circumstance that could lead to the termination of the Merger Agreement.
• Potential legal proceedings or litigation against the Company and its directors/officers following the announcement of the Merger Agreement.
• Risks that the proposed merger disrupts current plans and operations of the Company.
• Potential difficulties in retaining employees as a result of the proposed transaction.
• Disruption of management's attention from ongoing business operations due to the proposed transaction.
• The effect of the announcement on the Company's relationships with referral sources, vendors, operating results, and business generally.
• Changes in global, regional, or local political, economic, business, competitive, market, or regulatory factors.
• Risks described in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2025, under 'Risk Factors' and subsequent SEC reports.

Future Outlook

The company expects the take-private transaction to close in the third fiscal quarter of 2026, subject to stockholder and regulatory approvals. Upon completion, FONAR's common stock will be delisted from Nasdaq and deregistered under the Exchange Act. The company will continue as a wholly-owned subsidiary of FONAR, LLC.

Management Comments

• FONAR Corporation confirmed it entered into a definitive agreement on December 23, 2025, with FONAR, LLC and FONAR Acquisition Sub, Inc., under which Buyer will acquire all issued and outstanding shares of the Company.
• The Special Committee unanimously recommended the entry into the Merger Agreement and the Transaction, and the Board (excluding directors that are members of the Acquisition Group who recused themselves from the vote) unanimously approved the entry into the Merger Agreement.

Industry Context

This take-private transaction for FONAR, a pioneer in MR scanning and medical imaging, reflects a trend where established, smaller public companies may seek private ownership to navigate market pressures, invest in long-term strategies, or streamline operations away from public scrutiny. The involvement of existing management in the acquisition group suggests a belief in the company's underlying value and future potential, possibly indicating a strategic shift or consolidation within the specialized medical device and diagnostic imaging sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for a detailed assessment against global benchmarks. It focuses on the terms of the take-private transaction and the premium offered to shareholders relative to its own historical stock prices.
• The premiums offered (31.5% over prior day close, 21.9% over initial proposal announcement, 39.7% over 90-day average) are generally considered attractive in take-private transactions, often exceeding typical market premiums for similar deals. However, without specific industry benchmarks for comparable medical imaging companies going private, a direct assessment of 'global benchmarks' is limited by the filing's content.

Management Changes

Corporate Governance

Legal Proceedings

• The company acknowledges the risk of legal proceedings being instituted against it and others following the announcement of the Merger Agreement.
• The company has agreed to cooperate with Parent in the defense and settlement of any such stockholder litigation and will not settle without Parent's prior written consent.

Related Party Transactions

• The acquisition group (FONAR, LLC and FONAR Acquisition Sub, Inc.) is led by the Company's Chief Executive Officer, Timothy Damadian, and includes Chief Operations Officer Luciano Bonanni and director Ron Lehman, who are members of Parent holding equity interests.
• These individuals are parties to Voting Agreements, committing their shares (6,622,872 voting securities) to vote in favor of the merger.
• The transaction is structured as a 'going private transaction' under Section 144(c) of the DGCL, which specifically addresses related-party transactions.
• The votes represented by the Subject Shares in the Voting Agreements will not be counted for purposes of obtaining the Disinterested Stockholder Approval, a measure to ensure fairness in the related-party transaction.

Stakeholder Impact

• Shareholders will receive a significant cash premium for their shares, providing immediate liquidity and a favorable exit. However, they will lose future participation in the company's growth as it becomes private.
• Employees face potential difficulties in retention, as noted in the forward-looking statements, although the company aims to preserve the services of current officers and key employees.
• Management, particularly the CEO, COO, and a director, are leading the acquisition group, indicating continued involvement and potential for long-term strategic execution in a private setting.
• Customers, suppliers, and vendors may experience effects on their relationships, operating results, and business generally due to the transaction, which the company aims to mitigate by preserving existing relationships.
• Creditors will see a change in the company's capital structure due to new debt financing, potentially impacting the company's credit profile as a private entity.

Next Steps

• Company to prepare and file a proxy statement on Schedule 14A with the SEC.
• Company and certain participants to jointly prepare and file a Rule 13E-3 transaction statement on Schedule 13E-3 with the SEC.
• Company to mail the definitive proxy statement, Schedule 13E-3, and proxy card to stockholders.
• Company to duly call, give notice of, convene, and hold a special stockholders meeting to vote on the merger agreement and obtain the Requisite Company Vote and Disinterested Stockholder Approval.
• Closing of the merger is expected within three business days after satisfaction or waiver of conditions, but no later than March 12, 2026 (subject to extensions).
• Company expects to release Q2 2025 financial results in February 2026.
• Upon completion, the Company Common Stock will be delisted from Nasdaq and deregistered under the Exchange Act.

Key Dates

Recommendation

The definitive merger agreement offers a substantial all-cash premium of 31.5% over the last trading day's closing price, 21.9% over the initial proposal announcement, and 39.7% over the 90-day average. This represents a highly attractive exit for shareholders. The transaction is fully financed and has received unanimous recommendation from an independent Special Committee and the Board (excluding interested directors), significantly de-risking the deal's completion. The requirement for disinterested stockholder approval adds a layer of protection for public shareholders. Given the high premium, cash consideration, and strong likelihood of closing, a seasoned investor would view this as a strong buy opportunity to capture the arbitrage spread until the merger closes.

Keywords

FONAR, FONR, Merger, Take Private, Acquisition, CEO-led buyout, Stockholder vote, Nasdaq delisting, Cash consideration, MRI, Medical imaging, Healthcare industry